| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rad51 Recombinase | 13 | 2021 | 81 | 3.560 |
Why?
|
| Homologous Recombination | 9 | 2022 | 57 | 2.180 |
Why?
|
| Radiation Injuries | 3 | 2019 | 157 | 1.220 |
Why?
|
| DNA Repair | 12 | 2021 | 362 | 1.100 |
Why?
|
| Radiotherapy | 5 | 2019 | 322 | 1.030 |
Why?
|
| Endometrial Neoplasms | 11 | 2001 | 237 | 0.940 |
Why?
|
| Small Molecule Libraries | 3 | 2016 | 73 | 0.860 |
Why?
|
| Neoplasms | 7 | 2016 | 3271 | 0.760 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 639 | 0.760 |
Why?
|
| Morpholines | 3 | 2015 | 64 | 0.760 |
Why?
|
| Transcription Factor RelB | 1 | 2022 | 3 | 0.740 |
Why?
|
| Benzamides | 3 | 2015 | 257 | 0.670 |
Why?
|
| Sulfonamides | 3 | 2015 | 344 | 0.610 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2019 | 96 | 0.600 |
Why?
|
| NF-kappa B | 1 | 2022 | 417 | 0.600 |
Why?
|
| Pyrroles | 4 | 2019 | 165 | 0.590 |
Why?
|
| Quinoxalines | 1 | 2019 | 51 | 0.580 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 2348 | 0.570 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 149 | 0.550 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1149 | 0.530 |
Why?
|
| Anthracyclines | 1 | 2017 | 31 | 0.500 |
Why?
|
| DNA Helicases | 2 | 2015 | 90 | 0.500 |
Why?
|
| Sarcoma | 3 | 2019 | 220 | 0.480 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 390 | 0.470 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 202 | 0.460 |
Why?
|
| DNA Replication | 4 | 2019 | 169 | 0.450 |
Why?
|
| Lung Neoplasms | 8 | 2023 | 2409 | 0.450 |
Why?
|
| Enzyme Activation | 2 | 2013 | 674 | 0.440 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 1080 | 0.430 |
Why?
|
| Radiotherapy, Conformal | 2 | 2007 | 87 | 0.410 |
Why?
|
| Adenocarcinoma | 6 | 2012 | 1198 | 0.400 |
Why?
|
| Drug Therapy | 1 | 2014 | 67 | 0.400 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2013 | 41 | 0.400 |
Why?
|
| Humans | 59 | 2023 | 96382 | 0.390 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 64 | 0.390 |
Why?
|
| Rec A Recombinases | 1 | 2013 | 14 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 1372 | 0.390 |
Why?
|
| Maleimides | 1 | 2012 | 26 | 0.380 |
Why?
|
| Nuclear Proteins | 2 | 2015 | 742 | 0.380 |
Why?
|
| DNA Damage | 3 | 2017 | 397 | 0.370 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2009 | 317 | 0.360 |
Why?
|
| Escherichia coli Proteins | 1 | 2013 | 183 | 0.350 |
Why?
|
| Indoles | 1 | 2013 | 332 | 0.350 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2022 | 72 | 0.340 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1248 | 0.340 |
Why?
|
| Cisplatin | 4 | 2009 | 575 | 0.340 |
Why?
|
| HEK293 Cells | 4 | 2019 | 706 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 2600 | 0.310 |
Why?
|
| Protein Binding | 5 | 2019 | 1540 | 0.300 |
Why?
|
| Neoplasm Staging | 15 | 2023 | 2055 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2009 | 522 | 0.300 |
Why?
|
| Cell Survival | 4 | 2019 | 1012 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 1504 | 0.290 |
Why?
|
| Molecular Structure | 3 | 2019 | 305 | 0.280 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 3221 | 0.280 |
Why?
|
| Apoptosis | 3 | 2019 | 1731 | 0.270 |
Why?
|
| Prognosis | 13 | 2021 | 4041 | 0.270 |
Why?
|
| DNA | 6 | 2021 | 1270 | 0.270 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2007 | 43 | 0.270 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 42 | 0.270 |
Why?
|
| Female | 35 | 2021 | 50528 | 0.260 |
Why?
|
| Structure-Activity Relationship | 3 | 2019 | 425 | 0.250 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 3969 | 0.250 |
Why?
|
| Aged | 25 | 2021 | 21309 | 0.250 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 2006 | 2 | 0.240 |
Why?
|
| Nasolacrimal Duct | 1 | 2006 | 3 | 0.240 |
Why?
|
| Genomic Instability | 3 | 2017 | 90 | 0.240 |
Why?
|
| Intubation | 1 | 2006 | 21 | 0.240 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2839 | 0.230 |
Why?
|
| Retrospective Studies | 19 | 2023 | 10719 | 0.230 |
Why?
|
| Ovariectomy | 3 | 2001 | 94 | 0.220 |
Why?
|
| Middle Aged | 27 | 2021 | 28794 | 0.220 |
Why?
|
| Adult | 23 | 2021 | 28968 | 0.200 |
Why?
|
| Hysterectomy | 3 | 2001 | 173 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 653 | 0.200 |
Why?
|
| Multiprotein Complexes | 2 | 2021 | 106 | 0.190 |
Why?
|
| Genes, p53 | 1 | 2003 | 108 | 0.190 |
Why?
|
| Attitude to Health | 1 | 2004 | 217 | 0.190 |
Why?
|
| Survival Analysis | 9 | 2017 | 1525 | 0.190 |
Why?
|
| Fractures, Spontaneous | 1 | 2023 | 16 | 0.190 |
Why?
|
| Combined Modality Therapy | 6 | 2013 | 1738 | 0.190 |
Why?
|
| HIV-1 | 2 | 2015 | 178 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2004 | 113 | 0.180 |
Why?
|
| Adenoviridae | 1 | 2003 | 340 | 0.180 |
Why?
|
| Treatment Outcome | 13 | 2017 | 9526 | 0.180 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 156 | 0.170 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 834 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 51 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2001 | 42 | 0.170 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 7277 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1722 | 0.170 |
Why?
|
| Orthopedics | 1 | 2023 | 135 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 107 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 136 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2023 | 155 | 0.170 |
Why?
|
| Brachytherapy | 6 | 2001 | 132 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2003 | 371 | 0.160 |
Why?
|
| Peptides | 1 | 2004 | 664 | 0.160 |
Why?
|
| Extremities | 2 | 2013 | 170 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 5 | 2001 | 577 | 0.150 |
Why?
|
| Ossification, Heterotopic | 1 | 2019 | 34 | 0.150 |
Why?
|
| Adnexa Uteri | 1 | 1999 | 11 | 0.150 |
Why?
|
| Cycloaddition Reaction | 1 | 2019 | 6 | 0.150 |
Why?
|
| Radiotherapy Dosage | 4 | 2009 | 478 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 414 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2001 | 1793 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 395 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 125 | 0.140 |
Why?
|
| Naphthyridines | 1 | 2019 | 26 | 0.140 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 206 | 0.140 |
Why?
|
| Survival Rate | 7 | 2021 | 2019 | 0.140 |
Why?
|
| Radiobiology | 1 | 2018 | 13 | 0.140 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 415 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 1999 | 342 | 0.130 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 519 | 0.130 |
Why?
|
| Male | 17 | 2021 | 46116 | 0.130 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 120 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2007 | 193 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2011 | 219 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 101 | 0.120 |
Why?
|
| Endosonography | 1 | 2017 | 102 | 0.120 |
Why?
|
| Risk | 3 | 2004 | 659 | 0.120 |
Why?
|
| Bronchi | 1 | 2017 | 227 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2011 | 1184 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2021 | 800 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2019 | 404 | 0.110 |
Why?
|
| Doxorubicin | 2 | 2009 | 285 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2011 | 1079 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 66 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 1089 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 399 | 0.100 |
Why?
|
| Fluorometry | 1 | 2013 | 30 | 0.100 |
Why?
|
| RNA Interference | 1 | 2014 | 381 | 0.100 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2013 | 101 | 0.090 |
Why?
|
| Mitomycin | 1 | 2012 | 30 | 0.090 |
Why?
|
| Chicago | 3 | 2001 | 1488 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2014 | 829 | 0.090 |
Why?
|
| Actuarial Analysis | 3 | 2001 | 60 | 0.090 |
Why?
|
| DNA, Single-Stranded | 2 | 2011 | 95 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2000 | 321 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2012 | 88 | 0.090 |
Why?
|
| Protein Subunits | 1 | 2012 | 121 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 250 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 37 | 0.090 |
Why?
|
| Virus Integration | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2001 | 9 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 111 | 0.090 |
Why?
|
| Life Tables | 2 | 2001 | 46 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2022 | 3563 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2011 | 80 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2007 | 350 | 0.080 |
Why?
|
| Cysteine | 1 | 2012 | 147 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2013 | 127 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2011 | 161 | 0.080 |
Why?
|
| Age Factors | 3 | 2007 | 1957 | 0.080 |
Why?
|
| Mice | 3 | 2019 | 12495 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2000 | 1007 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2001 | 64 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 467 | 0.080 |
Why?
|
| Animals | 4 | 2019 | 28471 | 0.080 |
Why?
|
| Child | 2 | 2016 | 7540 | 0.080 |
Why?
|
| Chromatin | 1 | 2014 | 450 | 0.080 |
Why?
|
| Binding Sites | 1 | 2012 | 1145 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2011 | 527 | 0.080 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 260 | 0.080 |
Why?
|
| Epirubicin | 1 | 2009 | 14 | 0.080 |
Why?
|
| Ifosfamide | 1 | 2009 | 37 | 0.080 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2003 | 0.070 |
Why?
|
| History, 19th Century | 1 | 2009 | 56 | 0.070 |
Why?
|
| Necrosis | 1 | 2009 | 211 | 0.070 |
Why?
|
| Enzyme Stability | 1 | 2008 | 47 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2647 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2009 | 191 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2009 | 332 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 836 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2011 | 343 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2009 | 318 | 0.070 |
Why?
|
| Platinum Compounds | 1 | 2007 | 29 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2006 | 295 | 0.060 |
Why?
|
| Ligands | 1 | 2008 | 484 | 0.060 |
Why?
|
| Quality of Life | 1 | 2016 | 1869 | 0.060 |
Why?
|
| Genes, BRCA2 | 1 | 2008 | 162 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 84 | 0.060 |
Why?
|
| Dacryocystorhinostomy | 1 | 2006 | 3 | 0.060 |
Why?
|
| Silicones | 1 | 2006 | 21 | 0.060 |
Why?
|
| Guanine | 1 | 2007 | 194 | 0.060 |
Why?
|
| Carboplatin | 1 | 2007 | 329 | 0.060 |
Why?
|
| Fibroblasts | 1 | 2008 | 759 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2017 | 3157 | 0.050 |
Why?
|
| London | 1 | 2004 | 15 | 0.050 |
Why?
|
| Bacteriophage M13 | 1 | 2004 | 8 | 0.050 |
Why?
|
| Safe Sex | 1 | 2004 | 24 | 0.050 |
Why?
|
| Pregnancy in Adolescence | 1 | 2004 | 27 | 0.050 |
Why?
|
| Condoms | 1 | 2004 | 41 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2004 | 175 | 0.050 |
Why?
|
| Radiation, Ionizing | 1 | 2004 | 123 | 0.050 |
Why?
|
| Adolescent | 3 | 2007 | 9948 | 0.050 |
Why?
|
| Peptide Library | 1 | 2004 | 86 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2004 | 101 | 0.050 |
Why?
|
| Awareness | 1 | 2004 | 90 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 176 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1805 | 0.050 |
Why?
|
| Focus Groups | 1 | 2004 | 208 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2006 | 962 | 0.050 |
Why?
|
| Stents | 1 | 2006 | 425 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2008 | 2481 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 150 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 554 | 0.050 |
Why?
|
| HIV Infections | 1 | 2011 | 1001 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2003 | 426 | 0.040 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2001 | 12 | 0.040 |
Why?
|
| Platinum | 1 | 2021 | 67 | 0.040 |
Why?
|
| Vaginal Neoplasms | 1 | 2001 | 84 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2021 | 403 | 0.040 |
Why?
|
| China | 1 | 2021 | 268 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1768 | 0.040 |
Why?
|
| Infant | 1 | 2007 | 3259 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1937 | 0.040 |
Why?
|
| Cryoelectron Microscopy | 1 | 2021 | 119 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 7318 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2001 | 155 | 0.040 |
Why?
|
| Vascular Neoplasms | 1 | 2000 | 21 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 344 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2007 | 3905 | 0.040 |
Why?
|
| Carcinoma | 2 | 2000 | 440 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 100 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2528 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 1999 | 652 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 2896 | 0.040 |
Why?
|
| Knee Prosthesis | 1 | 2019 | 24 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2478 | 0.040 |
Why?
|
| Oxygen | 1 | 2004 | 782 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 311 | 0.040 |
Why?
|
| Vagina | 1 | 2000 | 185 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2021 | 913 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 889 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 120 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2019 | 116 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1999 | 145 | 0.030 |
Why?
|
| Pregnancy | 1 | 2004 | 3193 | 0.030 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2015 | 17 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2011 | 231 | 0.030 |
Why?
|
| Stilbenes | 1 | 2015 | 26 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 25 | 0.030 |
Why?
|
| Mutagens | 1 | 2015 | 29 | 0.030 |
Why?
|
| Replication Protein A | 1 | 2015 | 16 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2015 | 46 | 0.030 |
Why?
|
| Remission Induction | 2 | 2011 | 741 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 266 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2000 | 810 | 0.030 |
Why?
|
| Virus Replication | 1 | 2015 | 290 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 562 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2011 | 5 | 0.020 |
Why?
|
| SEER Program | 1 | 2013 | 239 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 18 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 414 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1313 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 263 | 0.020 |
Why?
|
| Time Factors | 1 | 1999 | 5524 | 0.020 |
Why?
|
| Risk Factors | 1 | 2001 | 6120 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 422 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 331 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1586 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 339 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1283 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 4742 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1792 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 162 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 122 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 153 | 0.010 |
Why?
|
| Mutation | 1 | 2008 | 4325 | 0.010 |
Why?
|
| Hospitalization | 1 | 2000 | 963 | 0.010 |
Why?
|